Gerrit Dispersyn - RXi Pharmaceuticals Chief Development Officer

Executive

Dr. Gerrit Dispersyn, Med. Sc. is Chief Development Officer of the Company. Dr. Dispersyn is an accomplished leader in clinical, product and business development. Dr. Dispersyn most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporationrationration. In this role, Gerrit was responsible for Integras global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integras Senior Management Leadership team, and several of the companys core teams for MA projects since 2017.
Tenure 7 years
Phone508-767-3861
Webhttp://www.rxipharma.com
Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues, and Cellular and Tissue based Products

RXi Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

EXECUTIVE Age

Selina ZhangHUTCHMED DRC
N/A
Melik UlusuCytek Biosciences
N/A
Nathan MinnichTreace Medical Concepts
N/A
Theresa MotaSunLink Health Systems
N/A
Catherine LundyXtant Medical Holdings
N/A
William McCombeCytek Biosciences
66
Aaron BeruttiTreace Medical Concepts
45
Valerie JDCytek Biosciences
48
Patrik JeanmonodCytek Biosciences
57
Scot ElderTreace Medical Concepts
49
Jill GilpinXtant Medical Holdings
N/A
Philippe BusqueCytek Biosciences
N/A
Kin MBAHUTCHMED DRC
47
Paul GoodeGlucoTrack
56
Julie DeweyTreace Medical Concepts
63
James MulliganSunLink Health Systems
102
Qingmei WangHUTCHMED DRC
61
Hong ChenHUTCHMED DRC
54
Mark SchallenbergerXtant Medical Holdings
38
David NgHUTCHMED DRC
N/A
Allen PoirsonCytek Biosciences
64
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and is traded on Nasdaq Capital Markets. It employs 15 people. RXi Pharmaceuticals (RXII) is traded on NASDAQ Exchange in USA and employs 15 people.

Management Performance

RXi Pharmaceuticals Leadership Team

Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geert Cauwenbergh, President CEO, Director
Robert Bitterman, Director
Pamela Pavco, Chief Devel. Officer
Keith Brownlie, Director
Jonathan Freeman, Independent Director
Gerrit Dispersyn, Chief Development Officer
Curtis Lockshin, Director
Paul Dorman, Independent Director
Alexey Eliseev, Chief Business Officer
Tamara McGrillen, IR Contact Officer

RXi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in RXi Stock

If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA